Hazards of chemical weapons release during war: New perspectives

Environmental Health Perspectives

Volumn 107, Issue 12, 1999, Pages 985-990

  Reutter, Sharon ^a  

^a EDGEWOOD CHEMICAL BIOLOGICAL CENTER   (United States)

Author keywords

Chemical weapons; Health effects; Mustard gas; Nerve gas; Potency; Toxicity

Indexed keywords

CHEMICAL WARFARE AGENT; MUSTARD GAS; NERVE GAS; VOLATILE AGENT;

EXPOSURE; FEMALE; HEALTH HAZARD; HUMAN; LIQUID; LONG TERM EXPOSURE; MALE; POPULATION EXPOSURE; PRIORITY JOURNAL; REVIEW; SOLDIER; TOXICOLOGY; WAR;

EID: 0033404103     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.99107985     Document Type: Review

References (105)

1. Murray VSG, Volans GV. Management of injuries due to chemical weapons. Br Med J 302:129-130 (1991).
2. Smith WJ, Dunn MA. Medical defense against blistering chemical warfare agents. Arch Dermatol 127:1207-1213 (1991).
3. Committee on Toxicology, National Research Council. Review of Acute Human-Toxicity Estimates for Selected Chemical-Warfare Agents. Washington, DC:National Academy Press, 1997.
4. Danon YL, Shemer J. Chemical Warfare Medicine Jerusalem:Gelen, 1994.
5. Stockholm International Peace Research Institute. Delayed Toxic Effects of Chemical Warfare Agents. Stockholm:Almqvist and Wiksell, 1975.
6. Mann I. A study of eighty-four cases of delayed mustard gas keratitis fitted with contact lenses. Br J Ophthalmol 28:441-447 (1944).
7. Amalric MP, Bessou P, Farenc M. Late recurrence of keratitis caused by mustard gas. Bull Soc Ophthalmol Fr 65:101-106 (1965).
8. Scholz RO, Woods AC. Relapsing and chronic mustard gas lesions of the eye. Chemical Warfare Medicine I CH. XII 260-278 (1946).
9. Case RAM, Lea AJ. Mustard gas poisoning, chronic bronchitis, and lung cancer. An investigation into the possibility that poisoning by mustard gas in the 1914-18 war might be a factor in the production of neoplasia. Br J Prev Soc Med 9:62-72 (1955).
10. Beebe GW. Lung cancer in World War I veterans: possible relation to mustard-gas injury and 1918 influenza epidemic. J Natl Cancer Inst 25:1231-1252 (1960).
11. Norman JE. Lung cancer mortality in World War I veterans with mustard-gas injury: 1919-1965. J Natl Cancer Inst 54:311-317 (1975).
12. Institute of Medicine. Veterans at Risk: The Health Effects of Mustard Gas and Lewisite. Washington, DC:National Academy Press, 1993.
13. Mioduszewski RJ, Reutter SA, Miller LL, Olajos EJ, Thomson SA. Evaluation of Airborne Exposure Limits for G-Agents: Occupational and General Population Criteria. ERDEC-TR-489. Aberdeen, MD:Edgewood Research, Development and Engineering Center, 1998.
14. Perrotta DM. Long-term Health Effects Associated with Sub-clinical Exposures to GB and Mustard. A review conducted by the Environment Committee, Armed Forces Epidemiological Board, 18 July 1996. Available: http:// www.gulflink.osd.mil/agent.html [cited 30 June 1999].
15. Baker DJ, Sedgwick E. Single fiber electromyographic changes in man after organophosphate exposure. Hum Exp Toxicol 15:369-396 (1996).
16. Maekawa K. The sarin poisoning incident in Tokyo subways. In: Proceedings of the 5th International Symposium on Protection Against Chemical and Biological Agents, Supplement, 11-16 June 1995, Stockholm, Sweden. Stockholm:FOA, 1995; 31-37.
17. Morita H, Yanagisawa N, Nakajima T, Shimizu M, Hirabayashi H, Okudera H, Hohara M, Midorikawa Y, Mimura S. Sarin poisoning in Matsumota, Japan. Lancet 346:290-293 (1995).
18. Okumura T, Takasu N, Ishimatsu S, Miyanoki S, Mitsuhashi A, Kumada K, Tanaka K, Hinohara S. Report on 640 victims of the Tokyo subway sarin attack. Ann Emerg Med 28:129-135 (1996).
19. Burchfiel JL, Duffy FH, Sim VM. Persistent effects of sarin and dieldrin upon the primate electroencephalogram Toxicol Appl Pharmacol 35:365-379 (1976).
20. Duffy FH, Burchfiel JL, Bartels PH, Gaon M, Sim VM. Long-term effects of an organophosphate upon the human electroencephalogram. Toxicol Appl Pharmacol 47:161-176 (1979).
21. Duffy FH, Burchfiel JL. Long term effects of the organophosphate sarin on EEGs in monkeys and humans. Neurotoxicology 1:667-689 (1980).
22. Sim VM, Duffy FH, Burchfiel JL, Gaon MD. Nerve Agents & Pesticides. Value of Computer Analysis of Electroencephalograms in the Diagnosis of Exposure to Organophosphates and Chlorinated Hydrocarbons. Aberdeen, MD:Biomedical Laboratory, 1971.
23. Somani SM, Babu SR. Toxicodynamics of sulfur mustard. Int J Clin Pharmacol 27:419-435 (1989).
24. Papirmeister B, Feister AJ, Robinson SI, Ford RD. Medical Defense against Mustard Gas. Boca Raton. FL:CRC Press, 1991.
25. Buscher H. Green and Yellow Cross: Special Pathology and Therapy of Injuries Caused by the Chemical War Materials of the Green Cross Group (Phosgene and Diphosgene) and of the Yellow Cross Group (Mustard Gas and Lewisite). Cincinnati, OH:Kettering Laboratory, 1944.
26. Heston WE. Carcingenic action of the mustards. J Natl Cancer Inst 11:415-423 (1950).
27. Taher AAY. Cleft lip and palate in Tehran. Cleft Palate-Craniofacial J 29:15-16 (1992)
28. Rozmiarek H, Capizzi RL, Papirmeister B, Furhman WH, Smith WJ. Mutagenic activity in somatic and germ cells following chronic inhalation of sulfur mustard. Mutat Res 21:13-14 (1973).
29. Wilson CM, Mackintosh JM. Mustard gas poisoning. Q J Med 13:210-239 (1920).
30. Marrs TC, Maynard RL, Sidell FR. Chemical Warfare Agents, Toxicology and Treatment. Chichester, UK:John Wiley and Sons, 1996.
31. Mellor SG, Rice P, Cooper GJ. Vesicant burns. Br J Plast Surg 44:434-437 (1991).
32. Borak J, Sidell FR. Agents of chemical warfare: sulfur mustard. Ann Emerg Med 21:303-308 (1992).
33. Warthin AS, Weller CV. The lesions of the respiratory and gastrointestinal tracts produced by mustard gas (dichlorethyl sulphide). J Lab Clin Med 4:229-264 (1919).
34. Peace Research Centre. The Gillis Report: Australian Field Trials with Mustard Gas 1942-1945. Canberra, Australia:The Australian National University, 1985.
35. Mann I, Pullinger BD. A study of mustard gas lesions of the eyes of rabbits and men. Proc R Soc Med XXXV:229-245 (1941).
36. Moore AM, Rockman JBA. Study of human hypersensitivity to compounds of the mustard gas type. Can J Res 28:169-176 (1950).
37. Klehr NW. Late manifestations in former mustard gas workers, with special considerations of the cutaneous findings. Z Hautkr 59:1161-1170 (1984).
38. Uhde GI. Mustard-gas burns of human eyes in World War II. Am J Ophthalmol 29:929-938 (1946).
39. Morgenstern P, Koss FR, Alexander WW. Residual mustard gas bronchitis. Effects of prolonged exposure to low gas concentrations of mustard gas. Ann Intern Med 26:27-40 (1947).
40. Nishimoto Y, Yamakido M, Shignobu T, Onari K, Yukutake M. Long term observation of poison gas workers with special reference to respiratory cancers. J UOEH 5(suppl):89-94 (1983).
41. Manning KP, Skegg DCG, Stell PM, Doll R. Cancer of the larynx and other occupational hazards of mustard gas workers. Clin Otolaryngol 6:165-170 (1981).
42. Weiss A, Weiss B. Carcinogenesis from exposure to mustard gas in man, an important point for therapy with alkylating agents. Otsch Med Wochenschr 100:919-923 (1975).
43. Wada S, Nishimoto Y, Miyanishi M, Katsuta S, Nishiki M. Malignant respiratory tract neoplasms related to poison gas exposure. Hiroshima J Med Sci 11:81-91 (1962).
44. Yamada A. On the late injuries following occupational inhalation of mustard gas, with special references to carcinoma of the respiratory tract. Acta Pathol Jpn 13:131-155 (1963).
45. Sato T, Utsumi S, Kajikawa K, Ikeda H. A case of cancer of the larynx found in mustard gas poisoning. J Otorhinolaryngol Soc Jpn 70:1773-1778 (1967).
46. Wada S, Miyanishi M, Nishimoto Y, Kambe S, Miller RW. Mustard gas as a cause of respiratory neoplasia in man. Lancet 1:1161-1163 (1968).
47. Inada S, Hiragun K, Seo K, Yamura T. Multiple Bowen's disease observed in former workers of a poison gas factory in Japan, with special reference to mustard gas exposure. J Dermatol 5:49-60 (1978).
48. Shigenobu T. Occupational lung cancer - respiratory cancers among retired workers of a poison gas factory. Jpn J Thoracic Dis 18:880-884 (1980).
49. Nishimoto Y, Burrows B, Myanashi M, Katsuta S, Shigenobu T, Kettel LJ. Chronic obstructive lung disease in Japanese poison gas workers. Am Rev Respir Dis 102:173-179 (1970).
50. Yanagida J, Hozawa S, Ishioka S, Maeda H, Tkahashi K, Oyama T, Takaishi M, Hakoda M, Akiyama M, Yamakido M. Somatic mutation in peripheral lymphocytes of former workers at the Okunojima poison gas factory. Jpn J Cancer Res 79:1276-1283 (1988).
51. Davis MIJ. The dermatologic aspects of the vesicant war gases. JAMA 126:209-213 (1944).
52. Alexander SF. Final Report of Bari Mustard Casualties Allied Force Headquarters, Office of the Surgeon, 1944.
53. Alexander SF. Medical report of Bari Harbor mustard casualties. Mil Surg 101:1-17 (1947).
54. Aasted A, Darre E, Wulf HC. Mustard gas: clinical, toxicological, and mutagenic aspects based on modern experience. Ann Plast Surg 19:330-333 (1987).
55. Wulf HC, Aasted A, Darre E, Niebuhr E. Sister chromatid exchanges in fishermen exposed to leaking mustard gas shells [Letter]. Lancet 1:690-691 (1985).
56. Balali M. Clinical and laboratory findings in Iranian fighters with chemical gas poisoning. In: Proceedings of the World's First Congress Biological and Chemical Warfare, 21-23 May 1984, Ghent Belgium. Ghent:Rijksuniverstiteit, 1984:254-259.
57. Balali-Mood M, Navaeian A. Clinical and paraclinical findings in 233 patients with sulfur mustard poisoning. In: Proceedings of New Compounds in Biological and Chemical Warfare, Second World Congress, International Association of Forensic Toxicologists, 23rd European International Meeting, 24-27 August 1986, Ghent, Belgium. Ghent:Rijksuniverstiteit, 1986;464-473
58. Requena L, Requena C, Sanchez M, Jaqueti G, Aguilar A, Sanchez-Yus E, Hernandaz-Moro B. Chemical warfare: cutaneous lesions from mustard gas. J Am Acad Dermatol 19:529-536 (1988).
59. Gilchrist HL, Matz PB. The Residual Effects of Warfare Gases I. Chlorine II. Mustard. Washington, DC:War Department, 1933.
60. Geeraets WJ, Abedi S, Blanke RV. Acute corneal injury by mustard gas. South Med J 70:348-350 (1977).
61. Hosseini K, Moradi A, Mansouri A, Vessal K. Pulmonary manifestation of mustard gas injury a review of 61 cases. Iran J Med Sci 14:20-25 (1989).
62. McNamara BP, Owens EJ, Christensen MK, Vocci FJ, Ford DF, Rozimarek H. Toxicological Basis for Controlling Levels of Mustard in the Environment. EB-SP-74030. Aberdeen, MD:Biomedical Laboratory, 1975.
63. Gage EL. Mustard gas burns - clinical experiences. W Va Med J 42:181-185 (1946).
64. Sinclair DC. Disability produced by exposure of skin to mustard-gas vapour. Br Med J 4649:346-347 (1950).
65. Reed CI. The minimum concentration of dichlorethylsulfide (mustard gas) effective for the eyes of man. J Pharm Exp Therap 15:77-80 (1920).
66. Momeni AZ, Enshaeih S, Meghdadi M, Amindjavaheri M. Skin manifestations of mustard gas, a clinical study of 535 patients exposed to mustard gas. Arch Dermatol 128:775-780 (1992).
67. Dixon M, Needham DM. Biochemical research on chemical warfare agents. Nature 158:432-438 (1946).
68. Leadbeater L. When all else fails. Chem Br 24:683-688 (1988).
69. Cullumbine H. Medical aspects of mustard gas poisoning. Nature 159:151-153 (1947).
70. Hughes WF. Mustard gas injuries to the eye. Arch Opthamol 27:582-601 (1942).
71. Renshaw B. Mechanisms in production of cutaneous injuries by sulfur and nitrogen mustards. In: Chemical Warfare Agents, and Related Chemical Problems, Vol 1, parts III-VI, Office of Scientific Research and Development. Washington, DC:National Defense Research Committee, 1946:479-520.
72. Anslow WP, Houck CR. Systemic pharmacology and pathology of sulfur and nitrogen mustards. In: Chemical Warfare Agents, and Related Chemical Problems, Vol 1, parts III-VI, Office of Scientific Research and Development. Washington, DC:National Defense Research Committee, 1946;470-478.
73. Dahl H, Gluud B, Vangsted P, Norn M. Eye lesions induced by mustard gas. Acta Ophthalmol Suppl 173:30-31 (1985).
74. Committee on Toxicology, Board on Toxicology and Environmental Health Hazards, Commission on Life Sciences, National Research Council. Possible Long-Term Health Effects of Short-Term Exposure to Chemical Agents, Vol 2, Cholinesterase Reactivators, Psychochemicals, and Irritants and Vesicants. Washington, DC:National Academy Press, 1984.
75. Watson AP, Jones TD, Adams JD. Relative potency estimates of acceptable residues and reentry intervals after nerve agent release. Ecotoxicol Environ Saf 23:328-342 (1992).
76. Craig FN, Cummings EG, Blevins WV. Pneumotachograms of troops masking in response to surprise chemical attack. Mil Med 129:150-156 (1964).
77. Dacre JC. Toxicology of some anticholinesterases used as chemical warfare agents - a review. In: Proceedings of the Second International Meeting on Cholinesterases, 17-21 September, 1983, Bled, Yugoslavia. Berlin:Walter de Gruyter, 1984;415-426.
78. Rickett DJ, Glenn JF, Houston WE. Medical defense against nerve agents, new directions. Mil Med 152:35-41 (1987).
79. Sidell FR. Clinical considerations in nerve agent intoxication. In: Chemical Warfare Agents (Somani S, ed). San Diego, CA:Academic Press, 1992;155-194.
80. Sidell FR, Borak J. Chemical warfare agents: II. Nerve agents. Ann Emerg Med 21:865-871 (1992).
81. Grob D, Harvey AM. The effects and treatment of nerve gas poisoning. Am J Med 14:52-63 (1953).
82. McNamara BP, Leitnaker F. Toxicological Basis for Controlling Emission of GB into the Environment. EASP 100-98, Washington, DC:Medical Research Laboratory, 1971.
83. Sidell FR, Groff WA. The reactivatibility of cholinesterase inhibited by VX and sarin in man. Toxicol Appl Pharmacol 27:241-252 (1974).
84. Maynard RL. Toxicology of chemical warfare agents. Gen Appl Toxicol 2:1253-1286 (1993).
85. Jimmerson VR, Shih TM, Mailman RB. Variability in soman toxicity in the rat: correlation with biochemical and behavioral measures. Toxicology 57:241-254 (1989).
86. Rubin LS, Krop S, Goldberg MN. Effect of sarin on dark adaptation in man: mechanism of action. J Appl Physiol 11:445-449 (1957).
87. Bowers MB, Goodman E, Sim VM. Some behavioral changes in man following anticholinesterase administration. J Nerv Ment Dis 138:383-389 (1964).
88. Grob D. The manifestations and treatment of poisoning due to nerve gas and other organic phosphate anticholinesterase compounds. Arch Int Med 98:221-239 (1956).
89. Gordon JJ, Inns RH, Johnson MK, Leadbeater L, Maidment MP, Upshall DG, Cooper GH, Rickard RL. The delayed neuropathic effects of nerve agents and some other organophosphorus compounds. Arch Toxicol 52:71-82 (1983).
90. Willems JL, Nicaise M, De Bisschop HC. Delayed neuropathy by the organophosphorus nerve agents soman and tabun. Arch Toxicol 55:76-77 (1984).
91. Munro NB, Ambrose KR, Watson AP. Toxicity of the organophosphate chemical warfare agents GA, GB, and VX: implications for public protection. Environ Health Perspect 102:18-38 (1994).
92. Van Kampen KR, James LF, Rasmussen J, Huffaker RH, Fawcett MO. Organic phosphate poisoning of sheep in Skull Valley, Utah. J Am Vet Med Assoc 154:623-630 (1369).
93. Van Kampen KR, Shupe JL, Johnson AE, James LF, Smart RA, Rasmussen JE. Effects of nerve gas poisoning in sheep in Skull Valley, Utah. J Am Vet Med Assoc 156:1032-1035 (1970).
94. Sidell FR. Soman and sarin: clinical manifestations and treatment of accidental poisoning by organophosphates. Clin Toxicol 7:1-17 (1974).
95. Grob D, Harvey JC. Effects in man of the anticholinesterase compound sarin (isopropyl methyl phosphonofluoridate). J Clin Invest 37:350-368 (1958).
96. Hoskins B, Fernando JCR, Dulaney MD, Lim DK, Liu DD, Watanabe HK, Ho IK. Relationship between the neurotoxicities of soman, sarin and tabun, and acetylcholinesterase inhibition. Toxicol Lett 30:121-129 (1986).
97. McNamara BP, Vocci FJ, Leitnaker FC. Proposed Limits for Human Exposure to VX Vapor in Nonmilitary Operations. EASP 1100-1(R-1). Aberdeen, MD:Department of the Army, 1973.
98. Manthei JH, Way RA, Gaviola BI, Burnett DC, Bona DM, Durst HD. Toxicological evaluation of VX decontamination wastestreams according to Department of Transportation (DOT) test procedures. ECBC-TR-011. Aberdeen, MD:Edgewood Research, Development and Engineering Center, 1999.
99. De Candole CA, Douglas WW, Lovatt EC, Holmes R, Spencer KEV, Torrance RW, Wilson KM. The failure of respiration in death by anticholinesterase poisoning. Br J Pharmacol 8:466-475 (1953).
100. Rickett DL, Glenn JF, Beers ET. Central respiratory effects versus neuromuscular action of nerve agents. Neurotoxicology 7:225-236 (1986).
101. Koelle GB. Pharmacology of organophosphates. J Appl Toxicol 14:105-109 (1984).
102. Sidell FR, Aghajanian GK, Groff WA. The reversal of anticholinergic intoxication in man with the cholinesterase inhibitor VX (37670). Proc Soc Exp Biol Med 144:725-730 (1973).
103. Sidell FR, Kaminskis A. The Influence of Age, Sex, and Oral Contraceptives on Human Blood Cholinesterase Activity. EB-TR-75019. Aberdeen, MD:Edgewood Arsenal, 1975.
104. U.S. EPA. Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry. EPA/600/6-90/066F. Washington, DC:U.S. Environmental Protection Agency, 1994.
105. Department of Health and Human Services, Centers for Disease Control. Final recommendations for protecting the health and safety against potential adverse effects of long-term exposure to low doses of agents: GA, GB, VX, mustard agent (H, HD, T) and Lewisite (L). Fed Reg 53:8504-8507 (1988).